BioSpace News Archive

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Deciphera Pharmaceuticals, Inc. announced that in connection with the hiring of Kelley Dealhoy, Senior Vice President and Chief Business Officer, the Compensation Committee of Deciphera’s Board of Directors approved the grant of a stock option to purchase 100,000 shares of Deciphera’s common stock and 45,000 restricted stock units to Ms. Dealhoy with a grant date of July 15, 2022.

Escend Pharmaceuticals, Inc., a privately held company focused on the development of small molecule therapeutics for oncology orphan diseases, announced that the United States Food and Drug Administration has cleared its investigational new drug application for its lead drug candidate, ES-3000 for a Phase I clinical trial in relapsed or refractory acute myeloid leukemia.

Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into agreements with Quoin Pharmaceuticals Inc. (NASDAQ: QNRX) for the development, registration, supply, commercialization and distribution of QRX003 on an exclusive basis in Canada.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business highlights.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

Synthetic Biologics, Inc., a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one share of common stock for every ten shares of common stock, effective as of 12:01 a.m. on July 25, 2022.

Scholar Rock today announced the company will present new data that highlight the development of its highly selective, context-dependent TGFβ1 antibody.

Awakn launches ‘Beta’ phase of its Licensing and Partnerships business in North America.

Nymox Pharmaceutical Corporation announced an update to its shareholders regarding progress in the Company business activities.